Amgen Inc. (AMGN), Friday, announced that the FDA has expanded UPLIZNA's label to include the treatment of generalized myasthenia gravis in adults who are positive for anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibodies.
The approval was based on results from a phase 3 trial, dubbed MINT, in which UPLIZNA showed strong efficacy at 26 weeks in both anti-acetylcholine receptor (AChR+) and anti-muscle-specific tyrosine kinase (MuSK+) antibody positive, with AChR+ patients continuing to improve through 52 weeks in the study.
Myasthenia gravis is a rare autoimmune disorder that affects the neuromuscular system, leading to severe muscle weakness and extreme fatigue. There are two main types, namely ocular and generalized. About 85% of patients with myasthenia gravis have the generalized form, or gMG.
Antibodies against AChR (Acetylcholine receptor) and MuSK (muscle-specific tyrosine kinase) are detected in patients with myasthenia gravis. Approximately 85% of patients with myasthenia gravis have detectable antibodies against AChR, and approximately 7% have detectable antibodies against MuSK.
This marks the third approved indication for UPLIZNA and makes it the first and only CD19-targeted B-cell therapy approved for adults with anti-AChR and anti-MuSK antibody-positive generalised myasthenia gravis.
UPLIZNA is already approved in the U.S. for the treatment of adult patients with anti-aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD) and for the treatment of adult patients with Immunoglobulin G4-related disease (IgG4-RD).
Sales of UPLIZNA were $379 million for the full year 2024, and $422 million in the first nine months of 2025.
On Thursday, AMGN closed trading at $317.38, up 0.63%.
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.